Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer.

Al Omari A, Abdelkhaleq H, Al-Hussaini M, Turfa R, Awad N, Hassan MM, Alfaqih MA, Garrett CR.

J Glob Oncol. 2018 Jul;4:1-10. doi: 10.1200/JGO.18.00018.

2.

Identification and characterization of RET fusions in advanced colorectal cancer.

Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, Ross JS, Stephens PJ, Miller VA, Ali SM, Chiu VK.

Oncotarget. 2015 Oct 6;6(30):28929-37. doi: 10.18632/oncotarget.4325.

3.

Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.

Hecht JR, Reid TR, Garrett CR, Beck JT, Davidson SJ, Mackenzie MJ, Brandt U, Rizvi S, Sharma S.

Anticancer Res. 2015 Mar;35(3):1567-73.

PMID:
25750312
4.

Association between KRAS mutation and lung metastasis in advanced colorectal cancer.

Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S.

Br J Cancer. 2015 Feb 3;112(3):424-8. doi: 10.1038/bjc.2014.619. Epub 2014 Dec 23.

5.

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS.

Clin Cancer Res. 2015 Feb 15;21(4):739-48. doi: 10.1158/1078-0432.CCR-14-1901. Epub 2014 Dec 16.

6.

High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study.

Tanasanvimon S, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR.

Thromb Res. 2014 Feb;133(2):154-7. doi: 10.1016/j.thromres.2013.10.027. Epub 2013 Oct 24.

PMID:
24331209
7.

Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.

Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):301-5. doi: 10.1016/j.ijrobp.2013.10.034. Epub 2013 Dec 5.

8.

Metformin use and improved response to therapy in rectal cancer.

Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S, Das P.

Cancer Med. 2013 Feb;2(1):99-107. doi: 10.1002/cam4.54. Epub 2013 Feb 3.

9.

Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.

Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM.

Cancer. 2013 Dec 15;119(24):4223-30. doi: 10.1002/cncr.28358. Epub 2013 Sep 16.

10.

Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science.

Sahin IH, Hassan MM, Garrett CR.

Cancer Lett. 2014 Apr 10;345(2):249-57. doi: 10.1016/j.canlet.2013.09.001. Epub 2013 Sep 7. Review.

PMID:
24021750
11.

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature.

Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR.

J Cancer. 2013;4(4):320-2. doi: 10.7150/jca.3619. Epub 2013 Mar 28.

12.

Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas.

Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, Cohen L.

Br J Cancer. 2012 Jul 24;107(3):411-6. doi: 10.1038/bjc.2012.283. Epub 2012 Jul 10.

13.

A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas.

Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR.

Int J Surg Oncol. 2012;2012:863034. doi: 10.1155/2012/863034. Epub 2012 May 16.

14.

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG.

Clin Cancer Res. 2012 Jun 1;18(11):3170-9. doi: 10.1158/1078-0432.CCR-11-3005.

15.

Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer.

Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM.

Br J Cancer. 2012 Apr 10;106(8):1374-8. doi: 10.1038/bjc.2012.71. Epub 2012 Mar 15.

16.

Accessing primary health care: a meta-ethnography of the experiences of British South Asian patients with diabetes, coronary heart disease or a mental health problem.

Garrett CR, Gask LL, Hays R, Cherrington A, Bundy C, Dickens C, Waheed W, Coventry PA.

Chronic Illn. 2012 Jun;8(2):135-55. doi: 10.1177/1742395312441631. Epub 2012 Mar 13.

PMID:
22414446
17.

Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary.

Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C.

Clin Colorectal Cancer. 2012 Sep;11(3):191-4. doi: 10.1016/j.clcc.2011.12.003. Epub 2012 Jan 26.

PMID:
22280844
18.

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS.

Br J Cancer. 2011 Jun 28;105(1):44-52. doi: 10.1038/bjc.2011.182. Epub 2011 May 31.

19.

Cetuximab in the treatment of patients with colorectal cancer.

Garrett CR, Eng C.

Expert Opin Biol Ther. 2011 Jul;11(7):937-49. doi: 10.1517/14712598.2011.582464. Epub 2011 May 11. Review.

PMID:
21557708
20.

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.

Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD.

Cancer Chemother Pharmacol. 2011 Aug;68(2):547-52. doi: 10.1007/s00280-011-1620-1. Epub 2011 Apr 24.

PMID:
21516509
21.

Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?

Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN.

Cancer. 2011 Oct 1;117(19):4484-92. doi: 10.1002/cncr.26036. Epub 2011 Mar 28.

22.

High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.

Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN.

J Clin Oncol. 2011 Mar 10;29(8):1083-90. doi: 10.1200/JCO.2010.32.6132. Epub 2011 Jan 24.

23.

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM.

Invest New Drugs. 2011 Dec;29(6):1381-9. doi: 10.1007/s10637-010-9479-2. Epub 2010 Jul 20.

24.

Reirradiation to the abdomen for gastrointestinal malignancies.

Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P.

Radiat Oncol. 2009 Nov 18;4:55. doi: 10.1186/1748-717X-4-55.

25.

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD.

Clin Cancer Res. 2009 Sep 15;15(18):5869-77. doi: 10.1158/1078-0432.CCR-08-2480. Epub 2009 Sep 8.

26.
27.

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S.

J Clin Oncol. 2008 Nov 10;26(32):5198-203. doi: 10.1200/JCO.2008.17.2064. Epub 2008 Sep 29.

28.

Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.

Cangiano J, Centeno BA, Garrett CR, Cáceres W, de Jesús A, Lee JH, Pavía O, Jove R, Báez L, Sullivan DM, Muro-Cacho CA, Muñoz-Antonia T.

Dig Dis Sci. 2008 Aug;53(8):2090-100. doi: 10.1007/s10620-007-0118-5. Epub 2008 Jan 26.

29.

Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia.

Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S, Coppola D.

Clin Colorectal Cancer. 2007 Sep;6(9):652-6.

PMID:
17945038
30.

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.

Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI.

Clin Cancer Res. 2007 Oct 1;13(19):5855-61.

31.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ.

J Clin Oncol. 2007 Aug 1;25(22):3230-7.

PMID:
17664471
32.

Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia.

Sagatys E, Garrett CR, Boulware D, Kelley S, Malafa M, Cheng JQ, Sebti S, Coppola D.

Hum Pathol. 2007 Oct;38(10):1526-31. Epub 2007 Jul 19.

PMID:
17640711
33.
34.

A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.

Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR.

Clin Cancer Res. 2007 Feb 1;13(3):986-93.

35.

Malignant pleural mesothelioma: a comprehensive review.

Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR.

Cancer Control. 2006 Oct;13(4):255-63. Review.

PMID:
17075562
36.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
37.

Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM.

Clin Cancer Res. 2006 Aug 1;12(15):4645-51.

38.

Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer.

Homsi J, Garrett CR.

Cancer Control. 2006 Jan;13(1):42-7.

PMID:
16508625
39.

Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.

Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2006 Jan 15;12(2):523-8.

40.

Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.

Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2005 May 1;11(9):3335-41.

41.

Barriers to health care for immigrants and nonimmigrants: a comparative study.

Garrett CR, Treichel CJ, Ohmans P.

Minn Med. 1998 Apr;81(4):52-5.

PMID:
9577539
42.

Monitoring blood levels of selected drugs. Remember to factor in the many confounding variables.

Keyler DE, VanDeVoort JT, Howard JE, Jancik JT, Garrett CR.

Postgrad Med. 1998 Mar;103(3):209-12, 215-9, 223-4. Review.

PMID:
9519039
43.

Skin necrosis secondary to low-molecular weight heparin in a patient with antiphospholipid antibody syndrome.

Gibson GE, Gibson LE, Drage LA, Garrett CR, Gertz MA.

J Am Acad Dermatol. 1997 Nov;37(5 Pt 2):855-9.

PMID:
9366852
44.

Covert hypothyroidism presenting as a cardiovascular event.

LeMar HJ Jr, West SG, Garrett CR, Hofeldt FD.

Am J Med. 1991 Nov;91(5):549-52.

PMID:
1951418
45.
46.

Detection of C. difficile toxin A (enterotoxin)

Peterson LR, Holter JJ, Shanholtzer CJ, Garrett CR, Gerding DN.

Am J Clin Pathol. 1987 Feb;87(2):298-9. No abstract available.

PMID:
3544806
47.

Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test.

Peterson LR, Holter JJ, Shanholtzer CJ, Garrett CR, Gerding DN.

Am J Clin Pathol. 1986 Aug;86(2):208-11.

PMID:
3739972
48.
49.
50.

Evaluation of the 24-h API 20A anaerobe system for identification of Clostridium difficile.

Gresser ME, Shanholtzer CJ, Gerding DN, Garrett CR, Peterson LR.

J Clin Microbiol. 1984 Jun;19(6):915-6.

Supplemental Content

Loading ...
Support Center